Gen1E Lifesciences is a pre-clinical stage biopharmaceutical company focused on transforming research in areas with unmet medical needs into therapies. Ge1E targets those therapies with commercial and technical attractiveness. Criteria that they look for include therapies that have huge unmet need, low competition, clear reimbursement and intellectual property, predictable animal data, objective clinical end point with a biomarker, qualify for FDA fast track, tax credit and marketing exclusivity.
The company developed a novel use for a natural peptide called MUC1-ED with antibacterial properties for treatment of Pseudomonas infections that can complement antibiotic-based therapies. The mechanism of action of MUC1-ED is different from traditional antibiotic therapies and could be used to reduce bacterial load, slow the development of resistance and shorten treatment duration.
Gen1E has a partnership with University of Maryland, Baltimore (UMB). In 2018 the company entered into an exclusive option agreement with UMB to license patent rights entitled “ MUC1 Decoy Petptides for Treatment and Prevention of Bacterial Infections” which was invented by Erik P. Lillehoj, Ph.D., Avelino C. Verceles, M.D. and Simeon E. Goldblum, M.D., all faculty members of the University of Maryland School of Medicine.
Gen1E also has an exclusive option with UMB for its p38a Kinase inhibitor for treatment of Acute Lung Injury/Acute Respiratory Distress Syndrome and various inflammatory and age-related diseases.
Alan J. Levy
Co-Founder and COO
Co-Founder and CEO